Cite
HARVARD Citation
Miles, D. et al. (n.d.). 1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC). European journal of cancer. pp. S287-S288. [Online].